Effect of timing of administration on the plasma ACE inhibitory activity and the antihypertensive effect of quinapril
- PMID: 1330398
- DOI: 10.1038/clpt.1992.158
Effect of timing of administration on the plasma ACE inhibitory activity and the antihypertensive effect of quinapril
Abstract
To assess whether timing of administration can influence the antihypertensive effect of quinapril, 18 patients with hypertension were studied with noninvasive ambulatory blood pressure monitoring. Quinapril, 20 mg, was given at 8 AM or 10 PM for 4 weeks in a double-blind crossover fashion. To study the pattern of angiotensin converting enzyme (ACE) inhibition with the two treatment regimens, plasma ACE activity was measured in seven subjects 2, 4, 8, 12 and 24 hours after quinapril administration. The 24-hour blood pressure profiles showed a more sustained antihypertensive action with the evening administration of quinapril compared with the morning administration of quinapril; as with the morning administration, a partial loss of effectiveness was observed during nighttime hours. Measurement of ACE activity showed that evening administration caused a less pronounced but a more sustained decline of plasma ACE. These findings show that 20 mg quinapril given once daily is effective in lowering blood pressure levels throughout a 24-hour period. The evening administration seems to be preferable because it causes a more favorable modulation of ACE inhibition and therefore determines a more homogeneous 24-hour blood pressure control.
Similar articles
-
Can an angiotensin-converting enzyme inhibitor with a short half-life effectively lower blood pressure for 24 hours?Am Heart J. 1992 May;123(5):1421-5. doi: 10.1016/0002-8703(92)91064-8. Am Heart J. 1992. PMID: 1575169 Clinical Trial.
-
Clinical pharmacology of quinapril in healthy volunteers and in patients with hypertension and congestive heart failure.Angiology. 1989 Apr;40(4 Pt 2):360-9. doi: 10.1177/000331978904000405. Angiology. 1989. PMID: 2539762 Clinical Trial.
-
Dose responses and pharmacokinetics for the angiotensin converting enzyme inhibitor quinapril.Clin Pharmacol Ther. 1992 Mar;51(3):260-5. doi: 10.1038/clpt.1992.20. Clin Pharmacol Ther. 1992. PMID: 1312002 Clinical Trial.
-
Quinapril. A reappraisal of its pharmacology and therapeutic efficacy in cardiovascular disorders.Drugs. 1994 Aug;48(2):227-52. doi: 10.2165/00003495-199448020-00008. Drugs. 1994. PMID: 7527326 Review.
-
Quinapril: a further update of its pharmacology and therapeutic use in cardiovascular disorders.Drugs. 2002;62(2):339-85. doi: 10.2165/00003495-200262020-00009. Drugs. 2002. PMID: 11817979 Review.
Cited by
-
Morning versus evening administration of nifedipine gastrointestinal therapeutic system in the management of essential hypertension.Clin Investig. 1994 Nov;72(11):864-9. doi: 10.1007/BF00190742. Clin Investig. 1994. PMID: 7894213 Clinical Trial.
-
Optimal timing for antihypertensive dosing: focus on valsartan.Ther Clin Risk Manag. 2007 Mar;3(1):119-31. doi: 10.2147/tcrm.2007.3.1.119. Ther Clin Risk Manag. 2007. PMID: 18360620 Free PMC article.
-
Antihypertensive response to combination of olmesartan and amlodipine does not depend on method and time of drug administration.High Blood Press Cardiovasc Prev. 2013 Mar;20(1):25-32. doi: 10.1007/s40292-013-0013-4. Epub 2013 May 9. High Blood Press Cardiovasc Prev. 2013. PMID: 23657962 Clinical Trial.
-
Chronotherapy for Hypertension.Curr Hypertens Rep. 2018 Sep 28;20(11):97. doi: 10.1007/s11906-018-0897-4. Curr Hypertens Rep. 2018. PMID: 30267334 Free PMC article. Review.
-
Evening versus morning dosing regimen drug therapy for hypertension.Cochrane Database Syst Rev. 2011 Oct 5;2011(10):CD004184. doi: 10.1002/14651858.CD004184.pub2. Cochrane Database Syst Rev. 2011. Update in: Cochrane Database Syst Rev. 2024 Feb 14;2:CD004184. doi: 10.1002/14651858.CD004184.pub3. PMID: 21975743 Free PMC article. Updated.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous